BRISTAFLAM 100 MG 20 F.C.TABS

INDICATIONS FOR ACECLOFENAC : 1. ANKYLOSING SPONDYLITIS 2. OSTEOARTHRITIS 3. SYMPTOMATIC TREATMENT OF PAIN AND INFLAMMATION IN POST-TRAUMATIC PAIN 4. CERVICAL PAIN 5. LOW BACK PAIN 6. ACUTE GOUT HALF LIFE: THE MEAN PLASMA ELIMINATION HALF-LIFE IS 4 - 4.3 HOURS CONTRA-INDICATIONS: 1. HYPERSENSITIVITY TO THE DRUG 2. BLEEDING FROM THE STOMACH OR INTESTINES 3. MODERATE TO SEVERELY DECREASED KIDNEY FUNCTION 4. HYPERSENSITIVITY TO OTHER NSAIDS 5. ACTIVE PEPTIC ULCER INTERACTIONS FOR ACECLOFENAC - MAY INCREASE PLASMA CONCENTRATIONS OF LITHIUM DIGOXIN AND METHOTREXATE. - ACTIVITY OF ANTICOAGULANTS MAY BE INCREASED. - INHIBITS THE ACTIVITY OF DIURETICS. WHEN CONCOMITANTLY ADMINISTRATED WITH - POTASSIUM SPARING DIURETICS SERUM POTASSIUM SHOULD BE MONITORED. - ACECLOFENAC MAY ENHANCE CYCLOSPORIN NEPHROTOXICITY. - MAY PRECIPITATE CONVULSIONS WHEN COADMINISTERED WITH QUINOLONE ANTIBIOTICS.